About Cerezyme^®

In 1991, Gaucher disease management shifted with the advent of targeted enzyme replacement therapy, developed by Genzyme Corporation in cooperation with the National Institute of Health.

With the introduction of Cerezyme® (imiglucerase for injection) in 1994, clinicians have been able to address the cause of disease initiation and progression itself, and therefore prevent, alleviate and even reverse many effects of non-neuronopathic Gaucher disease.

Since its approval, Cerezyme has become the standard of care for patients who require treatment for Gaucher disease.^[2,3,4,5] This has not changed with the arrival of an alternative treatment approach, substrate inhibition, which is indicated for the treatment of mild to moderate type I Gaucher patients, but may be used only in the treatment of ADULT patients for whom ERT is unsuitable. ^[2,3,4,5]

Cerezyme is indicated for long term enzyme replacement therapy for adult and pediatric patients with a confirmed diagnosis of Gaucher disease. ^[1] It is administered by intravenous infusion and is well tolerated. Adverse reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population: nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia.

Please report all adverse events promptly to Genzyme Belgium by completing an Adverse Event Form and fax it to +32 2 714 17 09. You can also e-mail at mdbelgium@genzyme.com or call at +32 2 714 17 11.

Cerezyme is available in 200 U and 400 U vials and is reimbursed in Belgium.

For more information on reimbursement of Cerezyme in Belgium, please contact us.

Please see the full prescribing information for Cerezyme® below:

References

1. Summary of Product Characteristics Cerezyme^®.

2. Summary of Product Characteristics Miglustat.

3. The Advisory Council to the European Working Group on Gaucher Disease (EWGGD) (2003). The role of the iminosugar N-butyldeoxynojirimycin (Miglustat) in the management of the type I (non-neuronopathic) Gaucher disease : A position statement. J. Inher. Metab. Dis. 26 (2003) 513-526

4. Pastores et al. Therapeutic Goals in the treatment of Gaucher disease Seminars in Hematology 2004; Vol 41, N°4, (suppl 5):4-14.

5. Weinreb NJ, Barranger JA, Charrow J, et al. Guidance on the use of miglustat for treating patients with type I Gaucher disease. Am J Hematol. 2005; 80(3):223-9.